Ligand Pharmaceuticals Inc
NASDAQ:LGND
Intrinsic Value
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. [ Read More ]
The intrinsic value of one
LGND
stock under the Base Case scenario is
73.02
USD.
Compared to the current market price of 71 USD,
Ligand Pharmaceuticals Inc
is
Undervalued by 3%.
Ligand Pharmaceuticals Inc's market capitalization is 1.2B USD.
LGND stock price is 71 USD.
LGND stock price (71 USD) is 3% less than its Intrinsic Value (73.02 USD).
LGND stock (52.73 USD) is 26% less than its price (71 USD). Open Relative Valuation
LGND has upside potential of 68% compared to the average analyst price target.
Open Wall St Estimates
LGND's ROIC (Return on Invested Capital) has decreased in the last 3 years from 2% to 1%.
LGND has positive Net Income for the last twelve months.
LGND's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
LGND's ROE (Return on Equity) has increased in the last 3 years from 6% to 8%.
LGND has positive Operating Income for the last twelve months.
LGND's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 1%.
LGND has positive three-year average ROIC (Return on Invested Capital): 5%. The company is efficient at using invested capital to generate operating income.
LGND's Revenue is forecast to grow at a rate of 20% per year over the next 3 years.
LGND has a very low three-year average ROE (Return on Equity): 3%. The company is not efficient at transforming stockholders' equity into net income.
LGND's Revenue has been falling by 11% per year for the last 3 years.
LGND's Revenue has dropped by 33% over the past 12 months.
LGND has positive Gross Profit for the last twelve months.
LGND has negative Free Cash Flow for the last twelve months.
LGND's short-term assets (237m USD) exceed its short-term liabilties (17m USD).
LGND's long-term assets (787m USD) exceed its long-term liabilties (86m USD).
LGND's D/E (Debt to Equity) is very low and is equal to 0.
LGND's Altman Z-Score is very high and is equal to 9.9.
LGND earns more than enough operating income (10m USD) to safely cover interest payments on its debt (288k USD).
Valuation Backtest
Ligand Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
LGND
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ligand Pharmaceuticals Inc
Balance Sheet Decomposition
Ligand Pharmaceuticals Inc
| Current Assets | 237.4m |
| Cash & Short-Term Investments | 170.3m |
| Receivables | 39.3m |
| Other Current Assets | 27.8m |
| Non-Current Assets | 549.8m |
| Long-Term Investments | 48.3m |
| PP&E | 25.1m |
| Intangibles | 470.3m |
| Other Non-Current Assets | 6.1m |
| Current Liabilities | 16.8m |
| Accounts Payable | 2.4m |
| Accrued Liabilities | 12.2m |
| Other Current Liabilities | 2.1m |
| Non-Current Liabilities | 69.5m |
| Other Non-Current Liabilities | 69.5m |
Earnings Waterfall
Ligand Pharmaceuticals Inc
|
Revenue
|
131.3m
USD
|
|
Cost of Revenue
|
-10.5m
USD
|
|
Gross Profit
|
120.8m
USD
|
|
Operating Expenses
|
-111m
USD
|
|
Operating Income
|
9.8m
USD
|
|
Other Expenses
|
42.3m
USD
|
|
Net Income
|
52.2m
USD
|
Free Cash Flow Analysis
Ligand Pharmaceuticals Inc
LGND Profitability Score
Profitability Due Diligence
Ligand Pharmaceuticals Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Ligand Pharmaceuticals Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
LGND Solvency Score
Solvency Due Diligence
Ligand Pharmaceuticals Inc's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Score
Ligand Pharmaceuticals Inc's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LGND Price Targets Summary
Ligand Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
LGND
is 119.14 USD
with a low forecast of 95.95 USD and a high forecast of 151.2 USD.
Ownership
LGND Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
LGND Price
Ligand Pharmaceuticals Inc
| Average Annual Return | -0.44% |
| Standard Deviation of Annual Returns | 35.63% |
| Max Drawdown | -65% |
| Market Capitalization | 1.2B USD |
| Shares Outstanding | 17 710 000 |
| Percentage of Shares Shorted | 5.54% |
Company Profile
Ligand Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. The company is headquartered in San Diego, California and currently employs 154 full-time employees. The firm is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The company has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its technologies include OmniAb Technologies, Pelican Expression Technology Platform, Captisol Technology, HepDirect, LTP, BEPro Technology Platform, and SUREtechnology Platform. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies. The Pelican Expression Technology is a scalable platform for recombinant protein production and is suited for complex, large-scale protein production. Captisol is a chemically modified cyclodextrin designed to optimize the stability of drugs.
Contact
IPO
Employees
Officers
The intrinsic value of one
LGND
stock under the Base Case scenario is
73.02
USD.
Compared to the current market price of 71 USD,
Ligand Pharmaceuticals Inc
is
Undervalued by 3%.
You don't have any saved screeners yet
